@article{fb507d341040414a8f43476cb5844134,
title = "The MAIT TCRβ chain contributes to discrimination of microbial ligand",
abstract = "Mucosal-associated invariant T (MAIT) cells are key players in the immune response against microbial infection. The MAIT T-cell receptor (TCR) recognizes a diverse array of microbial ligands, and recent reports have highlighted the variability in the MAIT TCR that could further contribute to discrimination of ligand. The MAIT TCR complementarity determining region (CDR)3β sequence displays a high level of diversity across individuals, and clonotype usage appears to be dependent on antigenic exposure. To address the relationship between the MAIT TCR and microbial ligand, we utilized a previously defined panel of MAIT cell clones that demonstrated variability in responses against different microbial infections. Sequencing of these clones revealed four pairs, each with shared (identical) CDR3α and different CDR3β sequences. These pairs demonstrated varied responses against microbially infected dendritic cells as well as against 5-(2-oxopropylideneamino)-6-d-ribitylaminouracil, a ligand abundant in Salmonella enterica serovar Typhimurium, suggesting that the CDR3β contributes to differences in ligand discrimination. Taken together, these results highlight a key role for the MAIT CDR3β region in distinguishing between MR1-bound antigens and ligands.",
keywords = "Antimicrobial responses, T-cell receptor, bacterial host response",
author = "Narayanan, {Gitanjali A.} and McLaren, {James E.} and Meermeier, {Erin W.} and Kristin Ladell and Swarbrick, {Gwendolyn M.} and Price, {David A.} and Tran, {Jessica G.} and Worley, {Aneta H.} and Todd Vogt and Wong, {Emily B.} and Lewinsohn, {David M.}",
note = "Funding Information: We thank Pamela Canaday and the OHSU Flow Cytometry Shared Resource for expert assistance. The following reagents were obtained through the NIH Tetramer Core Facility: MR1/5‐OP‐RU and MR1/6FP tetramers. The MR1/5‐OP‐RU tetramer technology was developed jointly by J. McCluskey, J. Rossjohn and D. Fairlie, and the material was produced by the NIH Tetramer Core Facility as permitted to be distributed by the University of Melbourne. This work was supported by Merit Review Award I01‐BX000533 (DML) from the United States Department of Veterans Affairs Biomedical Laboratory Research; resources and the use of facilities at the VA Portland Health Care System; National Institute of Allergy and Infectious Diseases R01‐AI048090 (DML); National Heart, Lung, and Blood Institute T32‐HL83808 (GAN, EWM); Wellcome Trust Senior Investigator Award 100326/Z/12/Z (DAP) and National Institute of Allergy and Infectious Diseases K08‐AI118538 (EBW). Research reported in this publication was supported by the Strategic Health Innovation Partnerships (SHIP) Unit of the South African Medical Research Council (SAMRC) with funds received from the South African Department of Science and Technology as part of a bilateral research collaboration agreement with the Government of India and from an SA MRC Collaborating Centre (ACT4TB/HIV). Funding Information: We thank Pamela Canaday and the OHSU Flow Cytometry Shared Resource for expert assistance. The following reagents were obtained through the NIH Tetramer Core Facility: MR1/5-OP-RU and MR1/6FP tetramers. The MR1/5-OP-RU tetramer technology was developed jointly by J. McCluskey, J. Rossjohn and D. Fairlie, and the material was produced by the NIH Tetramer Core Facility as permitted to be distributed by the University of Melbourne. This work was supported by Merit Review Award I01-BX000533 (DML) from the United States Department of Veterans Affairs Biomedical Laboratory Research; resources and the use of facilities at the VA Portland Health Care System; National Institute of Allergy and Infectious Diseases R01-AI048090 (DML); National Heart, Lung, and Blood Institute T32-HL83808 (GAN, EWM); Wellcome Trust Senior Investigator Award 100326/Z/12/Z (DAP) and National Institute of Allergy and Infectious Diseases K08-AI118538 (EBW). Research reported in this publication was supported by the Strategic Health Innovation Partnerships (SHIP) Unit of the South African Medical Research Council (SAMRC) with funds received from the South African Department of Science and Technology as part of a bilateral research collaboration agreement with the Government of India and from an SA MRC Collaborating Centre (ACT4TB/HIV). Publisher Copyright: {\textcopyright} 2020 Australian and New Zealand Society for Immunology Inc.",
year = "2020",
month = oct,
day = "1",
doi = "10.1111/imcb.12370",
language = "English (US)",
volume = "98",
pages = "770--781",
journal = "Immunology and Cell Biology",
issn = "0818-9641",
publisher = "Nature Publishing Group",
number = "9",
}